Avidian Wealth Solutions LLC Boosts Stake in Sanofi (NASDAQ:SNY)

Avidian Wealth Solutions LLC lifted its position in shares of Sanofi (NASDAQ:SNY) by 3.7% during the 4th quarter, HoldingsChannel reports. The fund owned 9,240 shares of the company’s stock after purchasing an additional 330 shares during the period. Avidian Wealth Solutions LLC’s holdings in Sanofi were worth $460,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the stock. Cardinal Capital Management raised its position in shares of Sanofi by 0.3% during the 4th quarter. Cardinal Capital Management now owns 58,854 shares of the company’s stock worth $2,927,000 after purchasing an additional 201 shares during the last quarter. Daiwa Securities Group Inc. raised its position in shares of Sanofi by 3.4% during the 4th quarter. Daiwa Securities Group Inc. now owns 6,541 shares of the company’s stock worth $325,000 after purchasing an additional 216 shares during the last quarter. Sage Rhino Capital LLC raised its holdings in Sanofi by 2.8% in the 3rd quarter. Sage Rhino Capital LLC now owns 8,722 shares of the company’s stock valued at $468,000 after acquiring an additional 240 shares during the last quarter. Gallacher Capital Management LLC raised its holdings in Sanofi by 4.5% in the 3rd quarter. Gallacher Capital Management LLC now owns 5,715 shares of the company’s stock valued at $307,000 after acquiring an additional 245 shares during the last quarter. Finally, Rise Advisors LLC raised its holdings in Sanofi by 98.4% in the 4th quarter. Rise Advisors LLC now owns 506 shares of the company’s stock valued at $25,000 after acquiring an additional 251 shares during the last quarter. Institutional investors and hedge funds own 10.04% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Morgan Stanley assumed coverage on shares of Sanofi in a report on Tuesday, January 23rd. They issued an “equal weight” rating and a $55.00 price objective for the company. TheStreet downgraded shares of Sanofi from a “b” rating to a “c” rating in a report on Friday, February 9th. Finally, StockNews.com downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 27th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, Sanofi has a consensus rating of “Moderate Buy” and an average price target of $55.00.

Sanofi Trading Up 0.7 %

Shares of SNY stock traded up $0.36 during trading on Monday, hitting $49.37. 628,599 shares of the stock traded hands, compared to its average volume of 2,019,866. The firm has a market capitalization of $124.89 billion, a P/E ratio of 24.63, a price-to-earnings-growth ratio of 1.37 and a beta of 0.61. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.87. The firm’s fifty day moving average price is $47.90 and its 200-day moving average price is $48.16. Sanofi has a 52-week low of $42.63 and a 52-week high of $55.72.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Thursday, February 1st. The company reported $0.89 EPS for the quarter, missing the consensus estimate of $0.94 by ($0.05). The firm had revenue of $11.76 billion for the quarter, compared to analysts’ expectations of $13.02 billion. Sanofi had a net margin of 10.52% and a return on equity of 19.69%. As a group, research analysts forecast that Sanofi will post 4.12 earnings per share for the current fiscal year.

Sanofi Increases Dividend

The company also recently declared an annual dividend, which will be paid on Thursday, June 6th. Stockholders of record on Friday, May 10th will be given a dividend of $1.478 per share. This represents a dividend yield of 2.98%. The ex-dividend date is Thursday, May 9th. This is a positive change from Sanofi’s previous annual dividend of $1.38. Sanofi’s payout ratio is presently 73.87%.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.